Overcome brain disorders with PET neuroimaging expert, NEUROPHET.
NEUROPHET Inc., with expertise in AI-based neuroimaging, we have been focusing on developing and providing innovative medical solutions for helping patients suffering from neurodegenerative disorders. To achieve the mission, we have applied the state-of-the-art AI technologies to our expertise in neuroimaging, brain modeling and neuromodulation. Neurophet has been focusing on diagnosis support and surrogate biomarkers for neurodegenerative disorders using AI-based neuroimaging analysis software, multi-modality of MRI and PET.
NEUROPHET SCALE PET is a US-FDA 510(k) cleared software for PET scan analysis. It provides Amyloid beta/Tau/FDG-PET regional quantification information by SUVR calculation in each brain ROIs with automatic processing and supports various PET tracers in the market.
Neurophet products are diagnosis support tools for brain disorders including Alzheimer's disease (AD) and stroke by brain region of interest (ROI) segmentation, measuring the volume of ROI and the status of biomarkers (Neurodegeneration, Amyloid-beta and Tau) related to diagnosis and therapeutics clinical trial, as surrogate biomarkers for subjects enrollment and outcome measurement.
Brands: NEUROPHET SCALE PET, NEUROPHET AQUA, NEUROPHET SegPlus, NEUROPHET tES LAB, NEUROPHET innk
NEUROPHET AQUA Official_v1_20210723
NEUROPHET SCALE PET DEMO Video